Literature DB >> 29456021

Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.

Peter Bannerman1, Fuzheng Guo1, Olga Chechneva1, Travis Burns1, Xiaoqing Zhu2, Yan Wang1, Bokyung Kim1, Naveen K Singhal3, Jennifer A McDonough3, David Pleasure4.   

Abstract

Canavan disease, a leukodystrophy caused by loss-of-function ASPA mutations, is characterized by brain dysmyelination, vacuolation, and astrogliosis ("spongiform leukodystrophy"). ASPA encodes aspartoacylase, an oligodendroglial enzyme that cleaves the abundant brain amino acid N-acetyl-L-aspartate (NAA) to L-aspartate and acetate. Aspartoacylase deficiency results in a 50% or greater elevation in brain NAA concentration ([NAAB]). Prior studies showed that homozygous constitutive knockout of Nat8l, the gene encoding the neuronal NAA synthesizing enzyme N-acetyltransferase 8-like, prevents aspartoacylase-deficient mice from developing spongiform leukodystrophy. We now report that brain Nat8l knockdown elicited by intracerebroventricular/intracisternal administration of an adeno-associated viral vector carrying a short hairpin Nat8l inhibitory RNA to neonatal aspartoacylase-deficient AspaNur7/Nur7 mice lowers [NAAB] and suppresses development of spongiform leukodystrophy.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Canavan disease; Nat8l knockdown; leukodystrophy

Mesh:

Substances:

Year:  2018        PMID: 29456021      PMCID: PMC5910673          DOI: 10.1016/j.ymthe.2018.01.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  Panglial gap junctional communication is essential for maintenance of myelin in the CNS.

Authors:  Oliver Tress; Marta Maglione; Dennis May; Tatjyana Pivneva; Nadine Richter; Julia Seyfarth; Sonja Binder; Armin Zlomuzica; Gerald Seifert; Martin Theis; Ekrem Dere; Helmut Kettenmann; Klaus Willecke
Journal:  J Neurosci       Date:  2012-05-30       Impact factor: 6.167

2.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

3.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

4.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

5.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.

Authors:  Jodi L McBride; Ryan L Boudreau; Scott Q Harper; Patrick D Staber; Alex Mas Monteys; Inâs Martins; Brian L Gilmore; Haim Burstein; Richard W Peluso; Barry Polisky; Barrie J Carter; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-08       Impact factor: 11.205

6.  N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.

Authors:  Jeremy S Francis; Ireneusz Wojtas; Vladimir Markov; Steven J Gray; Thomas J McCown; R Jude Samulski; Larissa T Bilaniuk; Dah-Jyuu Wang; Darryl C De Vivo; Christopher G Janson; Paola Leone
Journal:  Neurobiol Dis       Date:  2016-10-04       Impact factor: 5.996

7.  Astroglial redistribution of aquaporin 4 during spongy degeneration in a Canavan disease mouse model.

Authors:  Tim Clarner; Nicola Wieczorek; Barbara Krauspe; Katharina Jansen; Cordian Beyer; Markus Kipp
Journal:  J Mol Neurosci       Date:  2013-11-24       Impact factor: 3.444

8.  Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design.

Authors:  J N Martin; N Wolken; T Brown; W T Dauer; M E Ehrlich; P Gonzalez-Alegre
Journal:  Gene Ther       Date:  2011-03-03       Impact factor: 5.250

9.  Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.

Authors:  Marisa I Mendes; Desirée Ec Smith; Ana Pop; Pascal Lennertz; Matilde R Fernandez Ojeda; Warsha A Kanhai; Silvy Jm van Dooren; Yair Anikster; Ivo Barić; Caroline Boelen; Jaime Campistol; Lonneke de Boer; Ariana Kariminejad; Hulya Kayserili; Agathe Roubertie; Krijn T Verbruggen; Christine Vianey-Saban; Monique Williams; Gajja S Salomons
Journal:  Hum Mutat       Date:  2017-02-14       Impact factor: 4.878

10.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.

Authors:  Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  Front Mol Neurosci       Date:  2017-06-02       Impact factor: 5.639

View more
  4 in total

1.  Pathophysiology and Treatment of Canavan Disease.

Authors:  David Pleasure; Fuzheng Guo; Olga Chechneva; Peter Bannerman; Jennifer McDonough; Travis Burns; Yan Wang; Vanessa Hull
Journal:  Neurochem Res       Date:  2018-12-08       Impact factor: 3.996

2.  Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene.

Authors:  Jianfei Chao; Lizhao Feng; Peng Ye; Xianwei Chen; Qi Cui; Guihua Sun; Tao Zhou; E Tian; Wendong Li; Weidong Hu; Arthur D Riggs; Reuben Matalon; Yanhong Shi
Journal:  iScience       Date:  2022-05-11

3.  Cell-Based Therapy for Canavan Disease Using Human iPSC-Derived NPCs and OPCs.

Authors:  Lizhao Feng; Jianfei Chao; E Tian; Li Li; Peng Ye; Mi Zhang; Xianwei Chen; Qi Cui; Guihua Sun; Tao Zhou; Gerardo Felix; Yue Qin; Wendong Li; Edward David Meza; Jeremy Klein; Lucy Ghoda; Weidong Hu; Yonglun Luo; Wei Dang; David Hsu; Joseph Gold; Steven A Goldman; Reuben Matalon; Yanhong Shi
Journal:  Adv Sci (Weinh)       Date:  2020-10-29       Impact factor: 16.806

Review 4.  Function of Akkermansia muciniphila in Obesity: Interactions With Lipid Metabolism, Immune Response and Gut Systems.

Authors:  Yu Xu; Ning Wang; Hor-Yue Tan; Sha Li; Cheng Zhang; Yibin Feng
Journal:  Front Microbiol       Date:  2020-02-21       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.